We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Constellation Healthcare Technologies | LSE:CHT | London | Ordinary Share | CMN SHS USD0.0001 (DI/REG S) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 216.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCHT
RNS Number : 2407L
Constellation Healthcare Tech, Inc
29 September 2016
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF Article 7 of EU Regulation 596/2014.
29 September 2016
Constellation Healthcare Technologies, Inc.
("Constellation Healthcare Technologies", "CHT", "Company" or the "Group")
Further re Acquisition of VEGA Medical Professionals LLC
Further to the announcement released on 23 September 2016, Constellation Healthcare Technologies, Inc., the US based Healthcare Services Company, announces that the shares potentially due to the vendors of Vega Medical Professionals LLC ("Vega") under the terms of the three year earn out have been allotted and will be held in an escrow account until such time as certain revenue and EBITDA targets have been met by VEGA. The maximum number of shares that could be issued under the terms of the earn out is 989,011 based on an issue price of GBP1.40 ("Deferred Consideration Shares").
Application has been made for the Deferred Consideration Shares to be admitted to trading on AIM and admission is expected to occur on 30 September 2016 ("Admission"). Following Admission, the total number of issued common shares in the Company will be 91,357,782. This figure has not changed from the announcement dated 23 September 2016 as the Deferred Consideration Shares were included in the calculation of this figure at that time. The Company does not hold any common shares in treasury and therefore this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.
Enquiries:
Constellation Healthcare c/o Redleaf Communications Technologies +44 (0)20 7382 Paul Parmar, Chief Executive 4730 Officer Sotirios 'Sam' Zaharis, Chief Financial Officer finnCap - Nominated Adviser and Joint Broker Julian Blunt / Scott Mathieson - corporate finance Simon Johnson - corporate +44 (0)20 7220 broking 0568 Stifel Nicholas Europe Limited - Joint Broker +44 (0)20 7710 Jonathan Senior / Ben Maddison 7600 Redleaf Communications - +44 (0)20 7382 PR adviser 4730 Charlie Geller / Sam Modlin constellation@redleafpr.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQAKCDDQBKDKCB
(END) Dow Jones Newswires
September 29, 2016 10:11 ET (14:11 GMT)
1 Year Constellation Healthcare Chart |
1 Month Constellation Healthcare Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions